Abstract
Respiratory syncytial virus (RSV) presents a significant health risk to young infants and substantially burdens already stretched health systems every winter. Ireland launched a RSV immunisation pathfinder programme for newborns and other clinically vulnerable infants in September of 2024. While a comprehensive evaluation of the programme is underway, we aimed to rapidly analyse the impact of the programme on infant RSV hospitalisations. Based on an analysis of notified RSV hospitalisations spanning this and four previous seasons using generalised additive models, we estimated that there was a 75% reduction in the incidence rate for nirsevimab eligible infants born this season, conditional on the age-group and season effects adjusted for in the model (incidence rate ratio 0.25; 95% CI 0.19 to 0.33). This corresponded to an estimated 532 RSV hospitalisations averted (95%CI 369 to 695) for this group, in this season.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any third party funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Use of the aggregated, notifiable disease data used in this analysis was approved by the Health Service Executive - Health Protection Surveillance Centre. Under the Infectious Diseases Regulations 1981, and subsequent amendments, the Health Protection Surveillance Centre is authorised by law to collect information from doctors and laboratories, via Medical Officers of Health (MoH), about diagnoses of certain infectious diseases in Ireland. These diseases are referred to as notifiable diseases. The law exists to monitor and control the occurrence of infectious diseases, and to help prevent further illness. The most recent amendment to the Regulations is the Infectious Diseases (Amendment) Regulations 2024 (S.I. No. 528 of 2024) - this contains the up to date list of notifiable diseases. The main aim is to protect the health and safety of the community. Research and audit are among the stated purposed of this data collection. More information can be found here: https://www.hpsc.ie/notifiablediseases/howwehandleyourdata/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors, and will be made publicly available following the final publication of the analysis.
